Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck & Co Extending Allergy Interests With House Dust Mite Filing

This article was originally published in Scrip

Executive Summary

Merck & Co has submitted a BLA for what is likely to be its third sublingual allergy immunotherapy (SLIT) tablet to become available in the US, one developed to treat house dust mite (HDM) allergies, an important cause of allergic rhinitis and allergic asthma that might boost so-far underwhelming US sales of its new allergy products.


Related Content

Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts